Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
LRMR 
Larimar Therapeutics Inc (LRMR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/06/2026: LRMR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $15.4
1 Year Target Price $15.4
| 10 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.9% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/06/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 287.58M USD | Price to earnings Ratio - | 1Y Target Price 15.4 |
Price to earnings Ratio - | 1Y Target Price 15.4 | ||
Volume (30-day avg) 11 | Beta 1.06 | 52 Weeks Range 1.61 - 5.37 | Updated Date 01/6/2026 |
52 Weeks Range 1.61 - 5.37 | Updated Date 01/6/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.96 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -42.99% | Return on Equity (TTM) -78.24% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 117235660 | Price to Sales(TTM) - |
Enterprise Value 117235660 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -4.13 | Shares Outstanding 83090392 | Shares Floating 37318267 |
Shares Outstanding 83090392 | Shares Floating 37318267 | ||
Percent Insiders 1.1 | Percent Institutions 103.14 |
About Larimar Therapeutics Inc
Exchange NASDAQ | Headquaters Bala Cynwyd, PA, United States | ||
IPO Launch date 2014-06-19 | CEO, President & Director Dr. Carole S. Ben-Maimon M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 65 | Website https://larimartx.com |
Full time employees 65 | Website https://larimartx.com | ||
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.